Core Insights - Oliveda International, Inc. has achieved a valuation of over $1 billion within two years, driven by its subsidiary Olive Tree People, which is recognized as the fastest-growing company in the waterless beauty segment [1][4]. Company Growth - Olive Tree People began operations in March 2023 from a garage in Venice Beach, initially processing around 40 orders per day, which surged to 10,000 orders daily within a few months [2]. - The company faced significant logistical challenges, including a 3,000% increase in production and managing backorders, but successfully expanded its warehouse capacity to support sales exceeding $100 million in two years [3][4]. Market Potential - The waterless beauty market is described as having almost limitless potential, with plans for expansion into Canada in summer 2025 and Europe in October 2025 [5]. - Waterless beauty has been recognized as "The Next Big Thing" by various industry publications, indicating strong market interest and consumer engagement [8]. Product and Brand Development - Oliveda International, Inc. specializes in waterless beauty products derived from mountain olive trees, with a focus on holistic and organic certifications [5]. - The company has developed unique treatment concepts that have been validated by conventional medicine, enhancing its credibility in the beauty industry [8]. Social Responsibility - The founder, Thomas Lommel, is also noted for his conservation efforts, protecting over 30,000 century-old mountain olive trees and providing water to communities in Africa through his foundation [6].

Ivry-sur-Seine, France — May 7, 2025 REGULATED INFORMATION Information regarding the arrangements for taking part in the combined general meeting (ordinary and extraordinary) of May 28, 2024 Conditions for obtaining or consulting the documents prepared for the meeting The shareholders of the Company are invited to participate in the Combined Shareholders’ Meeting (ordinary and extraordinary) to be held on Wednesday, May 28, 2025 at 4.30 pm (Paris time) at: Urban Station - ESPACE DU CENTENAIRE 189, rue de ...

Amsterdam, 7 May 2025 (Regulated Information) --- AMG Critical Materials N.V. (“AMG”, EURONEXT AMSTERDAM: “AMG”) reports first quarter 2025 revenue of $388 million, an 8% increase compared to the first quarter 2024 revenue of $358 million. AMG achieved an adjusted EBITDA of $58 million, an 88% increase compared to the first quarter of 2024 adjusted EBITDA of $31 million. AMG had positive cash from operating activities of $9 million during the first quarter of 2025, compared to the $15 million of cash used i ...

Octopus Future Generations VCT plc Annual Report for the period ended 31 December 2024 and Notice of Meeting Further to the announcement of annual results for the period ended 31 December 2024, Octopus Future Generations VCT plc (the ‘Company’) announces that the Annual Report has been posted or otherwise made available to shareholders. A copy of the Annual Report is also available to view on the Company’s website at http://www.octopusinvestments.com The Annual Report includes the Notice of Meeting for the ...

DALLAS, May 07, 2025 (GLOBE NEWSWIRE) -- Twin Hospitality Group Inc. (“Twin Hospitality”) (NASDAQ: TWNP), the operating unit for the Twin Peaks and Smokey Bones restaurant brands, today announced that the Company will host a conference call to review its first quarter 2025 financial results on Thursday, May 8, 2025 at 6:00 PM ET. A press release with first quarter 2025 financial results will be issued prior to the conference call that day. The conference call can be accessed live over the phone by dialing 1 ...

Växjö, Sverige, 7:e maj 2025 * * * JLT Mobile Computers, informerar att årsstämma i JLT Mobile Computers AB (publ) hölls onsdagen den 7e maj 2025 i Växjö där följande huvudsakliga beslut fattades. Årsstämman beslutade att fastställa framlagd resultat- och balansräkning för moderbolaget och koncernen. Årsstämman beslutade, i enlighet med styrelsens förslag, att ingen utdelning lämnas till aktieägarna för räkenskapsåret 2024. Styrelseledamöterna och verkställande direktören beviljades ansvarsfrihet för 2024 å ...

NANTERRE (FRANCE)MAY 7th, 2025 COMBINED GENERAL MEETING OF MAY 28th, 2025 AVAILABILITY OF PREPARATORY DOCUMENTS FORVIA (hereinafter the “Company”) informs its shareholders that they are convened to the Combined Shareholders' Meeting to be held on May 28th, 2025, at 10 a.m. (Paris time) at the registered office in Nanterre. The meeting notice published in the Bulletin des annonces légales obligatoires (BALO) on April 23rd, 2025, and the convening notice which will be published in the BALO and in the legal ga ...

VALNEVA Declaration of shares and voting rights April 30, 2025__________________________________________________________________________________________ Company name: VALNEVARegistered office: 6 rue Alain Bombard, 44800 Saint-Herblain (France)Regulated market of Euronext Paris - Compartment B Declaration date: May 7, 2025 Number of shares composing the share capital of ValnevaTotal number of voting rights including suspended voting rights*Description of the change Date on which this change was recognizedTo ...

NUMBER OF SHARES COMPOSING CURRENT SHARE CAPITAL AND TOTAL NUMBER OF VOTING RIGHTS AS OF 30 APRIL 2025 Regulated Information Paris, 7 May 2025 Information about the total number of voting rights and shares pursuant to Article L.233-8 II of the French Commercial Code and Article 223-16 of the AMF General Regulations. DateNumber of shares composing current share capitalTotal number ofvoting rights30 April 2025800,316,777Gross: 888,385,614 Press contacts: Jean-Baptiste Froville_+33 1 58 98 68 00_ jean-baptiste ...

Core Points - The European Medicines Agency (EMA) has initiated a review of Valneva's chikungunya vaccine IXCHIQ due to reports of serious adverse events (SAEs) in elderly individuals, leading to a temporary suspension of its use for those over 65 years old [1][2] - A total of 17 SAEs, including two deaths, have been reported globally among elderly individuals with significant underlying medical conditions [2] - The exact cause of these SAEs and their relationship to the vaccine remain undetermined, and healthcare professionals are reminded not to administer IXCHIQ to individuals with weakened immune systems [3] Company Overview - Valneva SE is a specialty vaccine company focused on developing, manufacturing, and commercializing vaccines for infectious diseases, addressing unmet medical needs [9] - The company has a strong track record of advancing multiple vaccines from early research and development to approvals, currently marketing three proprietary travel vaccines [10] - Valneva is also developing vaccine candidates for Lyme disease, Zika virus, and other global public health threats [10] Industry Context - Chikungunya virus (CHIKV) is a mosquito-borne disease that has been identified in over 110 countries, with significant economic and medical burdens expected to grow due to climate change [8] - Between 2013 and 2023, more than 3.7 million chikungunya cases were reported in the Americas, highlighting the disease as a major public health concern [8]